<SEC-DOCUMENT>0001070081-25-000018.txt : 20250506
<SEC-HEADER>0001070081-25-000018.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250506160336
ACCESSION NUMBER:		0001070081-25-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		25917136

	BUSINESS ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20250506x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/6/2025 5:30:25 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 072ccef0-7207-4e2a-933e-89272a6b51c8 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20250506" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>PTC THERAPEUTICS, INC._May 6, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityCentralIndexKey" id="Tc_FGvsRKqDB0KzEdeVvpFWGw_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:AmendmentFlag" id="Tc_GBmAfsjbWESRe2jFTmSgTg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20250506.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_96648a38_c0f7_4684_b696_b5d7445d59a6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:DocumentType" id="Narr_qRCkjATXF0C6uSrOWcGy4Q"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_ObjY-cnCsEW3fJukJ1MwZQ"><b style="font-size:9pt;font-weight:bold;">May 6, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityRegistrantName" id="Narr_uLJJFsiuMkWK35SemqgWBw"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_Soc0dYLnLkW9azfl9tjkmw_2_0"></a><a id="Tc_wBp_rn3A10OgIP96Zivvaw_2_2"></a><a id="Tc_9dlFtpP8pEu9yiwLAhKCug_2_4"></a><a id="Tc_1IF8DdX2C0-PcTSNpYPa7A_3_0"></a><a id="Tc_f4dLPenFGkO1l8xCKuLWgQ_3_2"></a><a id="Tc_XH8xlNGDy0OYL271cfBStg_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_rRX2X0jGkkueuEouEo_WwQ_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityFileNumber" id="Tc_he-Ueg1-ckq5nTd49sXUQw_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityTaxIdentificationNumber" id="Tc_SvkRASlTSEe_Apzznb0HlQ_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_L-EHCOGpkEifimALFmrn7w_2_0"></a><a id="Tc__DU0TiEarkOu6li_G8128Q_3_0"></a><a id="Tc_t1zK-9_PVEaGh9a-hPtlVQ_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityAddressAddressLine1" id="Tc_9NoOl8Y31U2pb9jdXdxiBw_1_0"><b style="font-size:9pt;font-weight:bold;">500 Warren Corporate Center Drive</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityAddressCityOrTown" id="Narr_srMuDe0nnkqVPHcrqjVgdw"><b style="font-size:9pt;font-weight:bold;">Warren</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityAddressStateOrProvince" id="Narr_voqxqsmtxE-x9ffbRHxJlQ"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:EntityAddressPostalZipCode" id="Tc_abvDG-2AuUCloiU7PNydZA_2_3"><b style="font-size:9pt;font-weight:bold;">07059</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:CityAreaCode" id="Narr_qpHWGG8ChkSaZP9GnZcyQw"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:LocalPhoneNumber" id="Narr_KV_mMTf-UE--BBwUumVzHA"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_Wf9L2g7Kyk2HL1Kr8_pSPg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_Vi-Hxx-YJUyGyxWBBRjGRw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_83ps9d3W0kKDpA8-JYZeOA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_ZquH1neVU0SMcfA3LA-soA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_HtFfxG5hMkiEFjn2FpH1mw_1_0"></a><a id="Tc_Gigy7OCA-Ei2BkxN6jUdMw_1_2"></a><a id="Tc_gLxrfFR-1kqIO59-PAseAA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:Security12bTitle" id="Tc_CADirve4ek6sq8Hf-c5WZg_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" name="dei:TradingSymbol" id="Tc_bXZEaNEEVEulLPCtfbqgzA_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_FenS0v8rCkihCGc89sJ9bA_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_1_JFDjah3Ua6dmR5knfbTQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a363a996_01ab_43f6_9b87_dea224f2b359"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;2.02.&#160;</b><b style="color:#212529;font-weight:bold;background:#ffffff;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">On May&#160;6, 2025,&#160;PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March&#160;31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on Form 8-K (this &#8220;Report&#8221;) and is incorporated by reference into this Item&#160;2.02.</span></p><a id="_ef00b37e_0b0d_46b9_95e8_1011d7b7e5f4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7.01.&#160;Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Company will host a conference call on May&#160;6, 2025, at 4:30&#160;p.m. eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended March</span>&#160;31, 2025<span style="color:#212529;">, as well as other corporate highlights and updates. Directions on how to access the conference call are included in the press release furnished as Exhibit&#160;99.1 hereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></p><a id="_28ab756a_ea8c_4351_94df_735dd5a3f688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250506xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated May 6, 2025 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e8cf83be_f354_496a_84d0_eb6891fd4fb5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 6, 2025</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20250506xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/6/2025 05:30:21 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="display:inline-block;width:206.21pt;"></font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides Corporate Update and </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reports First Quarter 2025 Financial Results</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Strong revenue performance of $190 million &#8211;&#160;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="color:#373737;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Positive CHMP opinion for Sephience</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;vertical-align:top;">&#8482;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;white-space:pre-wrap;"> (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date &#8211;  </i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Global Sephience launch activities progressing well &#8211; </i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Strong cash position of over $2.0 billion as of March 31, 2025 &#8211;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">WARREN, N.J., May 6, 2025</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year revenue guidance,&#8221; said Matthew B. Klein, M.D., Chief Executive Officer. &#8220;Our strong cash balance supports all of our planned commercial and R&amp;D activities and provides the ability to reach cashflow breakeven without raising additional capital. The positive CHMP opinion for Sephience</font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> </i><font style="font-family:'Arial','Helvetica','sans-serif';">kickstarts our anticipated global launch for what we see as a significant revenue opportunity.&#8221; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Corporate Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">First quarter 2025 total net product and royalty revenue of $190 million.    </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">First quarter 2025 revenue for the DMD franchise of $134 million, including net product revenue for Translarna</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">&#8482;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> of $86 million and for Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> of $48 million.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 40.5pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Clinical and Regulatory Milestones:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Sephience </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Positive CHMP opinion on Sephience MAA for adult and pediatric PKU patients received on April 25, 2025; the opinion includes a broad label inclusive of all ages and disease severities. PTC expects the EC to adopt the opinion in approximately two months</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">NDA currently under review by the FDA, with a target regulatory action date of July 29, 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Japan regulatory submission under review and a decision is expected in Q4 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Vatiquinone</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">NDA for pediatric and adult patients with Friedreich&#8217;s ataxia accepted and granted Priority Review by the FDA, with a target regulatory action date of August 19, 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Translarna</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">NDA currently under review by the FDA </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">PTC518 </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Phase 2 PIVOT-HD study results announced on May 5, 2025: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Met primary endpoint of dose-dependent blood HTT lowering at Week 12</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Dose-dependent trends of clinical benefit in Stage 2 patients at Month 12 </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Signals of dose-dependent clinical benefit relative to matched natural history cohort and dose-dependent lowering of NfL in Stage 2 subjects at Month 24  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Continued favorable safety and tolerability with no treatment-related NfL spikes</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Plans to complete additional analyses and discuss next development and regulatory steps, including potential for accelerated approval     </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 45pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">First Quarter 2025 Financial Highlights:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Total net product and royalty revenue was $189.9 million for the first quarter of 2025, compared to $208.8 million for the first quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Total revenue includes net product revenue across the commercial portfolio of $153.4 million for the first quarter of 2025, compared to $177.6 million for the first quarter of 2024. Total revenue also includes royalty, collaboration and license, and manufacturing revenue of $1,022.7 million for the first quarter of 2025, compared to $32.5 million for the first quarter of 2024. The first quarter of 2025 collaboration and license revenue includes $986.2 million, related to the PTC518 license and collaboration agreement with Novartis, which closed in January 2025.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Translarna net product revenues were $86.2 million for the first quarter of 2025, compared to $103.6 million for the first quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Emflaza net product revenues were $47.8 million for the first quarter of 2025, compared to $57.5 million for the first quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Roche reported Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> full year 2025 sales of approximately 420 CHF million, resulting in royalty revenue of $36.4 million to PTC for first quarter 2025, as compared to $31.2 million for first quarter 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&amp;D expenses were $109.0 million for the first quarter of 2025, compared to $116.1 million for the first quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Non-GAAP R&amp;D expenses were $100.3 million for the first quarter of 2025, excluding $8.7 million in non-cash, stock-based compensation expense, compared to $107.2 million for the first quarter of 2024, excluding $9.0 million in non-cash, stock-based compensation expense. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">GAAP SG&amp;A expenses were $81.0 million for the first quarter of 2025, compared to $73.3 million for the first quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Non-GAAP SG&amp;A expenses were $71.6 million for the first quarter of 2025, excluding $9.4 million in non-cash, stock-based compensation expense, compared to $63.9 million for the first quarter of 2024, excluding $9.4 million in non-cash, stock-based compensation expense. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Net income was $866.6 million for the first quarter of 2025, compared to net loss of $91.6 million for the first quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities were $2,027.2 million as of March 31, 2025, compared to $1,139.7 million as of December 31, 2024.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Shares issued and outstanding as of March 31, 2025 were 79,225,276.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Updates Full-Year 2025 Financial Guidance:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">PTC now anticipates full-year 2025 revenue to be between $650 million and $800 million, which includes in-line products, potential new product launches, and royalty revenue from Evrysdi.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">PTC anticipates full-year 2025 GAAP R&amp;D and SG&amp;A expense to be between $805 and $835 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">PTC anticipates full-year 2025 non-GAAP R&amp;D and SG&amp;A expense to be between $730 and $760 million, excluding estimated non-cash, stock-based compensation expense of $75 million.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&amp;D and SG&amp;A </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:9pt;line-height:1.28;text-align:center;margin:0pt 146.45pt 8pt 134.05pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;"><br></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consolidated</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Statements</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">of</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Operations</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><font style="font-family:'Times New Roman','Times','serif';">(In</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';">thousands, except</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';">share and per</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';">share</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';">data)</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.2%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:middle;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:middle;width:25.63%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Three Months Ended March 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Revenues:</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net product revenue</font></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 153,426</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 177,604</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Collaboration and license revenue</font></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 986,231</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Royalty revenue</font></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 36,439</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 31,154</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Manufacturing revenue</font></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,360</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total revenues</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,176,096</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 210,118</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Operating expenses:</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">12,862</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 14,740</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Amortization of acquired intangible assets</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 3,798</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 51,530</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Research and development (1)</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 108,973</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 116,129</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Selling, general and administrative (2)</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 80,961</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 73,272</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Change in the fair value of contingent consideration</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (800)</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (100)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Tangible asset impairment and losses on transactions, net</font></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 77</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total operating expenses</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 205,871</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 255,571</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Income (loss) from operations</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 970,225</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (45,453)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Interest expense, net</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (34,092)</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (40,834)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Other (expense) income, net</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (6,305)</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,591</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Income (loss) before income tax expense</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 929,828</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (84,696)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Income tax expense</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (63,266)</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (6,880)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net income (loss) attributable to common stockholders</font></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 866,562</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (91,576)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Weighted-average shares outstanding:</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Basic (in shares)</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 78,115,836</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,496,127</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Diluted (in shares)</font></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 86,385,922</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,496,127</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net income (loss) per share&#8212;basic (in dollars per share)</font></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 11.09</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (1.20)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net income (loss) per share&#8212;diluted (in dollars per share)</font></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 10.04</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (1.20)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(1) Research and development reconciliation</b></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP research and development</font></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 108,973</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 116,129</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,663</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,967</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP research and development</b></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 100,310</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 107,162</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</b></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP selling, general and administrative</font></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 80,961</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 73,272</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 9,397</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 9,411</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP selling, general and administrative </b></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 71,564</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 63,861</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="color:#104861;font-family:'Aptos Display';font-size:20pt;line-height:1.28;margin:0pt 0pt 4pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:18pt;visibility:hidden;">&#8203;</font></p><p style="color:#104861;font-family:'Aptos Display';font-size:20pt;line-height:1.28;margin:3.5pt 0pt 4pt 0pt;"><font style="margin-top:18pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:9pt;line-height:1.28;text-align:center;margin:0.5pt 146.45pt 8pt 134.05pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary Consolidated Balance Sheets</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><font style="font-family:'Times New Roman','Times','serif';">(in thousands, except share data)</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.62%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">March 31, 2025</b></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:17.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and marketable securities</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2,027,181</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 1,139,696</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,655,387</b></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;"> 1,705,024</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total debt</font></p></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">285,712</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">285,412</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total deferred revenue</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">12,833</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5,505</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total liability for sale of future royalties</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2,098,463</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2,081,776</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,841,147</b></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,803,095</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total stockholders&#39; deficit (79,225,276 and 77,704,188 common shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively)</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(185,760)</font></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(1,098,071)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities and stockholders&#39; deficit</b></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,655,387</b></p></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1,705,024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.8%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="color:#104861;font-family:'Aptos Display';font-size:9pt;line-height:1.28;margin:18pt 0pt 4pt 168.5pt;">PTC Therapeutics, Inc.</p><p style="font-family:'Aptos';font-size:9pt;line-height:1.28;text-align:center;margin:0.4pt 53.15pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2025 R&amp;D and SG&amp;A Expense</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><font style="font-family:'Times New Roman','Times','serif';">(In millions)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low End of Range</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High End of Range</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Projected GAAP R&amp;D and SG&amp;A Expense</font></p></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 805</font></p></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 835</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Less: projected non-cash, stock-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 75</font></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 75</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense </b></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 730</font></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 760</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0.4pt 52.9pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.4pt 52.9pt 0pt 60.5pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Acronyms:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHF: Confoederatio Helvetica Francs (Swiss francs)</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHMP: Committee for Medicinal Products for Human Use</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DMD: Duchenne Muscular Dystrophy</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">EC: European Commission </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FDA: U.S. Food and Drug Administration</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP: Generally Accepted Accounting Principles</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HD: Huntington&#8217;s Disease</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HTT: Huntingtin protein</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">MAA: Marketing Authorization Application</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NDA: New Drug Application</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NfL: Neurofilament light chain</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">nmDMD: Nonsense mutation Duchenne muscular dystrophy</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PDUFA: Prescription Drug User Fee Act</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PKU: Phenylketonuria</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">R&amp;D: Research and Development</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SG&amp;A: Selling, General, and Administrative</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#39;s Conference Call and Webcast Reminder: </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">To access the call by phone, please&#160;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">click here</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investors section of the PTC website at&#160;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">https://ir.ptcbio.com/events-presentations</b><font style="font-family:'Arial','Helvetica','sans-serif';">. A replay of the call will be available approximately two hours after completion of&#160;the call and will be archived on the company&#39;s website for 30 days.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;and follow on Facebook, X, and LinkedIn.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For more information please contact:</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors:</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Ellen Cavaleri</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (615) 618-8228</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">ecavaleri@ptcbio.com</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media:</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Updates Full Year 2025 Financial Guidance&quot;, including with respect to (i) 2025 total revenue guidance and (ii) 2025 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance,&quot; &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia and other regions; </font><font style="font-family:'Arial','Helvetica','sans-serif';">the effect of the European Commission&#8217;s adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna on other regulatory bodies;</font><font style="font-family:'Arial','Helvetica','sans-serif';"> PTC&#39;s ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC&#39;s interpretation of the results of clinical trials and the totality of clinical data from its trials in Translarna; expectations with respect to PTC&#39;s license and collaboration agreement with Novartis Pharmaceuticals Corporation including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to Sephience, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under PTC&#39;s SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; PTC&#39;s ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi, Waylivra, Sephience or vatiquinone.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20250506.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 5:30:32 PM-->
<!--Modified on: 5/6/2025 5:30:32 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20250506" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20250506" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250506_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250506_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250506_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>tmb-20250506_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 5:30:32 PM-->
<!--Modified on: 5/6/2025 5:30:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20250506.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>tmb-20250506_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 5:30:32 PM-->
<!--Modified on: 5/6/2025 5:30:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>tmb-20250506_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 5:30:32 PM-->
<!--Modified on: 5/6/2025 5:30:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20250506.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638821494326938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638821494326938746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638821494326948743" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638821494326948743" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638821494326948743" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638821494326948743" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638821494326948743" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638821494326948743" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638821494326948743" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638821494326948743" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638821494326948743" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638821494326948743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638821494326948743" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638821494326958730" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638821494326958730" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638821494326958730" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638821494326958730" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638821494326958730" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638821494326958730" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638821494326958730" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638821494326958730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638821494326958730" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638821494326968730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638821494326968730" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638821494326968730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638821494326968730" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638821494326968730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638821494326968730" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Warren Corporate Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '& IEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( '& IEKF^1N8[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M/UY_ 5!+ 0(4 Q0    ( '& IEI&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ <8"F6N;Y&YCN
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ <8"F6IE<G",0!@  G"<  !,              ( !X $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !Q@*9:4TN^MU<$  "]$   &
M            @($A"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ <8"F6I^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !Q@*9:EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " !Q@*9:'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ <8"F6B0>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ <8"F6F60>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20250506x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20250506.xsd</File>
    <File>tmb-20250506_def.xml</File>
    <File>tmb-20250506_lab.xml</File>
    <File>tmb-20250506_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20250506x8k.htm">tmb-20250506x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20250506x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20250506",
   "dts": {
    "schema": {
     "local": [
      "tmb-20250506.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20250506_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20250506_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20250506_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20250506x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250506x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250506x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001070081-25-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-25-000018-xbrl.zip
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M)\U5-6EX,[UV1?_> $/?S,4L&9Z[UE@Y+=\@Y"X@(H0TKMQVR2\6!1<K6:W
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M'6S@^64ACW\&]<740W#[8+?&V[.CGG[U&1)PRM-]UXV0:B=49,OO4$L#!!0
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MTHR5:,)R03?),J>X+U$K-Y!V:QQ=^Z\=/XJKVS/]3M;V]G]02P,$%     @
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M,O(%'J/B'J)H^Y0-:W[*AITIMC8^^*09]\CSQR;YO#/ ;M>P.-]V0+H<?Q_
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M>SP G3@K8PE6M"B09LI 18\H):52/C^EY*R1"A\OFPM%(P-D)H>&G,0I!ZW
M)*&HYL5")%4S!QO0\PQVA1*J';>0F.,S4/'C:YKS;05C0X+1MD%- @]8W0M0
M\Z#KS814?#.XT]&(^_'E>GPR'MT<'K9N3UK#MR 5TV&A032N!T1"R&-.$!-2
MD3KC8R(3>3X3UMR*Q7L0BZ9+J*V@1V&R Y3HE,:]TO64BU+..9ZDY6[X_MF1
M4RUS7W[\)%?5MR >,#Q.38QO->LAY#5.W%6BTW%6DICPA:W,O$.9:7A>0-S%
MDO/S+C@5+/+MFF]?J'HU=U[E//MOEIP<X?*[ZB,D)WIA*SD/)! L#4XD)K:A
M.TE<<$B=!P_^FBJUR-$$<E3^@G.]HAS@4EF72%X29:E0$.2\IJJRHA5$F4@Y
M4E:QDE?%^#352;[NJ7^LCTX*O8N^43^^M<1CYU08Q.DZJ9HG1G=<NJI5N;HA
M'O9'E\7;:^TBWEN9JMD]'[GZ<8L3^G>-JX+$-:L>J5:C37*O-0=X36>QE#*2
MM,V'?,9\R)[A$PX:4*E%H.B:K(3QY2TAGCLQ59"V_+_E_W=)B%C_E_-;M+]8
M,G9D?V<.\W=&#Y_5OXD4V*<LN'7HM2WAD:AJ#ZDF]KS)#'4=&N$AU+![<QSL
M3N=5SY,AO!09#Z<//PHC2=/TEEG#Q2S/(72-=VDVU)8QGLX8D<Y^PXP1'WC*
M5 :)8PVVA8#D\&3J&Z?1\R3=&MZD\HQ(>L"[3H;)N%)&G&.CS66U1.&'L2 J
M3&M/\CYKU2/#O2=YTB]Z=^53G5,+-S^[T<;:95$G&E<#LK5]6^WOH?_E,SPO
M() ]=(_-@""'7IS48V==/1#86I,N>%<)A&G#\%KX^KF8.#(JH4V9<+#R_6<=
M7];KW^J!>=ZL^;IRU_U5C8[]71HW[=0Z6^Y<YT$/*>OT/KAS=BF"FK3YLP9C
M]1L'UZ?'L=/+ 8G5YN_+;JUO]&HG:EGRODA*-3J->AD#7V)/PW?HQ+05;*(V
M,8GJHPOL]HG_6[Y^EUF^<Q.WAJ7191*"E#%269(9%/=A+D+8&6 SR5^&AV $
M!%#9I7/;KFL/_1Y=;8F/;M>(;ECAP>V)!!>^@.:O[9C>UI%#N[1B:9\EN<25
MH2]@%8>>_4X3"A/K-J+"B0L:7'0/R*1ENGPS?2_1=N:-+R<\KQ;=.:@_0/QG
MN/IC^4IGN,4G!N^$01==*I!8Y!3D+\='M[B7N\9%;= J]"U=Z7Q]PB+G[]<O
MWS=[S6L<?8D.H3L$%BHD8RX1M0?JABE\4#>6S180 X^P6H"G*-V5NL,LL(;"
MNT I.[&^S#'MG-Z)S7)9+1@*E+@$T +O@1+#EDKSD["JTM-P:65Z(["&7<T+
M$UVUI:N7N5V<7KU,:J<,>@2[S3/8F[Y,\MEN#4V'"!9= IJ<ICWACM"7QL7#
M<*X!LM2MTH\#DZ7'1''S56T,_R1\I@+2]/>_4N%VK/9!VP261M>O;;<2$SIQ
M%6\$KLCXJ4NX,)J/=9"-"C:'>.Q%,WUZ:WT\T:],>(5>SHW""X!1XC,=[_9B
MX94O%HXR)'"NF,.25)1Y 2MR/J<794DIEV2-8%',ZZ*2*TA1CL*Z!0F%M)MN
M15P6T&OX)-IT 1ZOF$G$-B=O1?PF"F)!E.9W14TYL_*/SOZQ_71>8/ILD^T5
M&*\HE0E,$#J>6*>:#=:2%F36G!BS!!5)P4V/:^$PKBQPR,8A4J+;TO;";^PV
M+7 RL$,"\*B]/7HP: ;M4FM)A5OD]Z/Y&_LF['^$T5O0O$H=#,#,U$J[$:ZH
M=:>OWP7LTB@4S@+ (51[89\Y(00A0WM&>F":B-V='AEIAVUK!K8D&*82!DV6
M8[X,3&.MT+R'4P:V$2>"A26<@4.A!ZYE>#UX 5-?I <*RP\[E:2,0&<(S.^H
M!?2\BGCK$XW[TDT[B.[7V645HJ&'Y8F1:^%&GOCH5.@'9DB3N^'I%I^HAQE^
M7)![1'2>5W(E(O,*K\GYHB+)4H&498$7!*VDE$A!SZ]5LF;-];PY6$W 2AE>
MB 2L1;J!&6Y2.CY"1X:GFK87N&3=DK" J1\V9&EYV#F@3!9?;#8T@-EZMN<C
MNN_5BND&.M6D7# G) C[* \6)7SJ9 89!%P)7&TA'R#>HVSFT EKN(]K(AH9
M!(X6G:^&;BYMWD^ 048.<+)'^9&^#'AXE!A%W)26IJ4X8( ."8 !?VT659CP
M,.H!G4U*ZU"S!0Z]W=&#(1AN*&\>Q4W/'E)X82Y.Q9-"-HM [))H;W$HL//"
M_!OQ!+"(;V?6/SM[ O\\ZRQR*9R/, (ATQM6Z+=3\63D %:,KQ&=[@&G@NTA
MJJ48]:ETLP\1>1"ES$>ZB (4IBZ>0I!&0.%JL9+4#9-HD8YD7 L.&<PN"+.:
M:8>LO&+$B+$K'H0LG[1%R<JQ6MZC3B/CZ2'XC<@+E%L:@62:F"#3P(Q\1@B/
MWP.)]D*@]F \;C0R(SFP90J>>:K1'LT'-XQ%(;7D,!B4LS[H'EU[)$!1ZD:/
MF*S0W:#$IW@$$P=]>^$]C&H:""]0P6>.X,B@*HQ@2!28T8%)#'?[ B1=F-7-
M41Z@2 V/RAQ428V2"K+.*DX9R+:8?M-8(>6#Y'96A5IB4 WLY!$ J<\&:R=[
M8GB+84QS9FPS0P@7V4JQC)52H8AE@LLJS$(+@BSE-5TNY0J:5L P*RV77]<L
M5)H:R>E,D9TY1:<J7E+"O.>;-TXN<(Z[9KW^O<G%PL.G[HM_]Y&?CXDJ;?J\
M6WY[WNTSX+DL9J3M";=K0_HC4WVHIOFS?*A93;0)A"RS6:EI^*6=^9.$L%#&
M7S@?;G[<ZSI+-1*M/Z3O1D[Q6YV^1\137<,)+Y!Z0C+;$EOZ$N<44K?DS]CT
MY9)AYG71K,,'7/34])?E=N 9E V.VZ1+Q1Q0T07'H$)"-9-:OOC/76#[^[_M
M+JRVOX-Z+EW"]@<*1P,>?($OCLA(DC0AT_,'RY:/5QP0?7/I+MDFBV:TPFC&
M'M*8!W6!QRB*%\712O"F%@=6)S3%?XT@"GS^[<OA6Q>Z#@O' 82(KI@AW;4'
MOXMT[T59'7X8K&NPG?3H^V'K?*/I67\4S_J]XF3+'"^:F2,\:=4T7A0HJWHY
MIQ!9SQ7R<EXJ8KF<UWB9*,6R).A:7E<*:PUTS OWXV*02S>;0ZO8#]PU'H*W
MD(7$"3C-1"I(F*ER%QAN%')9-?2X(,5%"\PQ4G% TU*2P;0P].7!.*& QK*@
M&X7TL*E3$T ;8B'"J (-M04TVL6:PX'?LUT8E)9YA5$8!@UGXK$=1"^M,RZ3
MES)2:1L46-^FO]707L@4E][ZM\7Z1JX>RK.[TK9H?Z$=KK]5-J]LN@FZGC[\
MO"/NK"34?(87GWMXR\S^G.<3!EU"]^<) 8@M'9]!.).DW.05/"] RR/PUBM)
M;_VQ3M[OS.<&8#X<5QY]NG]H;EYP<^[\,+)>%C4- JXH.G'QO?&$N[3?FA9X
MG7Q%=W[]*6<]*Z!;KGE%7,/V;+\)MJGU#*(G<G3#VW!F^6=3D:U-!8G>"IQK
MW0*0C&=$V?>IB$;Z&=U'D@MY;';GP+UM:(LW#DQV!F056QO#GYX_, _^'U!+
M P04    " !Q@*9:2W4.<WHL  #T;P( %P   '1M8BTR,#(U,#4P-GAE>#DY
M9#$N:'1M[7U[>]LVTN]7P4F[7><YE"+J+KG-<UP[:;IMTFSLO'OV3XB$)-04
MP0*D'?73OS, *5$7R[I0-FUCMTEL2L1E\)O[ /CQ_U0J[\(Q#3WFDP]7'W\G
MOO"2"0MCXDE&8WAZR^,QN1)11$/RD4G)@X#\++D_8H2XM2K\!W\UFI7*VQ^A
ML?/T+1'V2>M-^TV]5F^16JO?J/7K+OG\D9Q\O3I_C5\>QY, _F;4?_OCA,64
M>&,J%8M_>O7UZGVE^^KMCS&/ _;VQS?9O^:[ ^%/W_[H\QNBXFG ?GHUH7+$
MPTHL(N@EBD_AS3?P\=)WOE5NN1^/^VZM]H_3B/H^#T>5@ WCONM6.^WY,\E'
MX_E#H7C,83*2!33F-PQ;W]#W!'X9,]U"HPV_Y_J$%Z/LM:$(X\J03G@P[?_S
M+(J%^N>I?J;XWPSZAC<#'K*L*;?J]DYC]BVNT("/8##X]-3TW4^GC*]GS?M<
M10&=]GFH6QD$PKM.AU*OM:MU-Z42O@,$73\JR6GP3^>?'UAPPV+N4?A9T5!5
M%)-\N#!<'('^]=8,=R "']I_]VW,!SPFO5[5_?'- /J+UJR,%S JX95X?+J\
M2.MH7Q0)/8 XDTLT/( 2BU/_?'5.KL9,TH@E\(8BGZ6XX3Y3Y%S(2$A@$?(U
M\O$?&OI$4Z>PSG\<R+?%MOB%P9AC1=YSJ6+R[X1*H!W1K/V>AR \H$7RA:DD
MB)7N.0_&G3I_]?:'[]QV[=3\G2'T@.8,,0YN9MVH$,X'P7%!"FEQL0I0_82'
M/OS6K^CO+$*6'\"\^&*?Q]"?IZ?8K;ON*;F,I0A'1+(;%B:,1$P.A9R@AB!B
M2+YW>S4"G03 F"1])2,++PE-\NOLB4#(_G>-#O[_=%\)5\\DW +-%@=?[Z;#
MJ( PB\6DWX67;K@"&1CP>-H?<Q]&G!*ZUGCN,/JLI?<-(^<?/GXF(N(A(@:@
M1"Y9-.8,\*01HY([)K_UZG2K]1:2FDG\6I!.'%2R&4VS6P=:0S?%S?)VS&-6
M41'U6#^2K'(+@AXZ(R>*19Q&0' >O@8.\A@0P"<\)&<1V$U:8CKDT\49<A=G
MM_#/A/)0@;5$8DF]:TV??R7!E-1[CA&PGR^^OC\C6E5DI"7E9+4#B6JY:0,W
M_1*( >C8&>N0@":A-R;4 QX#/@/+(I)B))E2,'ARR\!(S]XM!BW/?=WOLPV/
MIF@]JL8DLW51Q0J09.3[>K5&!JF>I0J??Z025KSAIH(A;::8U;UO]L]OO8]D
M^?_G[,N7=Y] R%?_575@R::D;=;K4+MXQL[+OH5#?@T]Z.ODT]GEQ=F_^_B%
MJ]<D%CYT3L-0)-JY!_]ZYGHD<]=C.+/?I;'?M0J*QPP^06/_K]389R#M_"4(
M5H]B%1<$O,QF+^.XNO5Z[?2]" )QB]*:DBGXP)KUDUC%L"SXE'UC7J)E O6D
M4(J 02ZG)(+UP*_B$IV+243#J0/RGHPIV%J#A >QMB;&7*5"!1Y/!$9TDHF)
MY2@1<'^M?<_#U95W",W&F2A %0FIE.(6ABK), F"BAY[UMHHX3XVY>A) EH5
MY0B;&-J])3]7R6\!XR$P1O4"('L.RFQ(WIF)PCC_& ZYQV25I"3Z _I0.2D)
M*E"/$XPYXY#"T S9)(G@HQ @ZHG)A$F-:,3WEQ_H)#J]R"M*?!QE_CC.EQI9
M@Y.3C + L;,A3)H,X/=KG)JF'*P.D91K#8M6 BX.=./1"$5;%;ER3O--9J]!
M9'$:Q:CX R!YS;UK !Z2%&E)0_@6CW0@;V0LC]3>P(G<CFF,B%.,H6:B1(':
MX+!R\-H,"$*O4!("7:L9%LK&BL];$_W&IBO1)M4_1G@&*1#300#R1TB?R9]>
MU5X1#TS0U):>_8X>4_9[VKUYHP)N>D CQ?K9#Z?[4S);O]K,+M?Q6?Q5C[(2
MT"FP<G_(OS$_'Z$U8\D6(I;PQU]+IBL^ ='Q"23:%P&2$XBDGR"QU@9'EUU3
M-+;0/\W[D:'07F0Z',1>2KUT/#]\UVMW>D#SV,^/:_%+A]II,]+FI$R(VB%8
M0%CZZ XW^/V"X:!MU5B J"(ABU'P^HD7:R$LQ90&('=G,F,QO%0EA,QE!D[[
M#:[)&[V(%G$O$7%KP97!)S-<+SY>D*$$0P%LH!14C68&*@>,'"](M(65QV.^
MD2MX6054AC1#7V%!JJUFN44DZX&IKJG8;<\"O]IS $J]FPP#^G>YR.1VFH])
MI69W)K_NEET%V0LD^].L55O'-X;2)SHR5GL&QA%TAO@Q?@(;)0&-!7A8'WG
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M>Q[T*AG\J3-=,]#7FX]7OF91_XQ0_^KM.3SD80)8'=(;(35T%!VR>*I1&HN
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M!H&]7I(?%/=[7A[RP6&]EQ.UZSJ]3L,JN&+B=I:+\F&Y%\-$+A8P[9&AMR:
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ML^2AQZ-@\?S]<HS_ T#Z@QEG+$(4U6[G5&^08[2,//CAZFH^8!YBDCQFO(3
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M$9=:X,7T6\Y2".BMFLD5X^E(;?V8U0=1A\K4# <HS[$H(\U8$CS=:RFOG0,
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M?\;Q)'C[OU!+ 0(4 Q0    ( '& IEJ[8$?TUP,  (4/   0
M  "  0    !T;6(M,C R-3 U,#8N>'-D4$L! A0#%     @ <8"F6E[\]4K?
M @  ] H  !0              ( !!00  '1M8BTR,#(U,#4P-E]D968N>&UL
M4$L! A0#%     @ <8"F6M5!#^NP!0  H4   !0              ( !%@<
M '1M8BTR,#(U,#4P-E]L86(N>&UL4$L! A0#%     @ <8"F6F*&-8IS!
MM24  !0              ( !^ P  '1M8BTR,#(U,#4P-E]P<F4N>&UL4$L!
M A0#%     @ <8"F6I\ILRKX%@  [Z\  !,              ( !G1$  '1M
M8BTR,#(U,#4P-G@X:RYH=&U02P$"% ,4    " !Q@*9:2W4.<WHL  #T;P(
M%P              @ '&*   =&UB+3(P,C4P-3 V>&5X.3ED,2YH=&U02P4&
2      8 !@"* 0  =54

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tmb-20250506x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20250506.xsd" xlink:type="simple"/>
    <context id="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_FGvsRKqDB0KzEdeVvpFWGw_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_GBmAfsjbWESRe2jFTmSgTg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_qRCkjATXF0C6uSrOWcGy4Q">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_ObjY-cnCsEW3fJukJ1MwZQ">2025-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_uLJJFsiuMkWK35SemqgWBw">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_rRX2X0jGkkueuEouEo_WwQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_he-Ueg1-ckq5nTd49sXUQw_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_SvkRASlTSEe_Apzznb0HlQ_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_9NoOl8Y31U2pb9jdXdxiBw_1_0">500 Warren Corporate Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_srMuDe0nnkqVPHcrqjVgdw">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_voqxqsmtxE-x9ffbRHxJlQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_abvDG-2AuUCloiU7PNydZA_2_3">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_qpHWGG8ChkSaZP9GnZcyQw">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_KV_mMTf-UE--BBwUumVzHA">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_Wf9L2g7Kyk2HL1Kr8_pSPg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_Vi-Hxx-YJUyGyxWBBRjGRw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_83ps9d3W0kKDpA8-JYZeOA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_ZquH1neVU0SMcfA3LA-soA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_CADirve4ek6sq8Hf-c5WZg_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_bXZEaNEEVEulLPCtfbqgzA_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Tc_FenS0v8rCkihCGc89sJ9bA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_6_2025_To_5_6_2025_CArBDyxyvUO_xwAHIxPr0g"
      id="Narr_1_JFDjah3Ua6dmR5knfbTQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
